Glycomimetics Inc financial data

Symbol
GLYC on Nasdaq
Location
9708 Medical Center Drive, Rockville, MD
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 560 % -30.7%
Debt-to-equity 21.1 % +49%
Return On Equity -161 % -118%
Return On Assets -133 % -106%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.5M shares +0.14%
Common Stock, Shares, Outstanding 64.5M shares +0.18%
Entity Public Float 109M USD +254%
Common Stock, Value, Issued 64.5K USD +0.18%
Weighted Average Number of Shares Outstanding, Basic 64.5M shares +0.21%
Weighted Average Number of Shares Outstanding, Diluted 64.5M shares +0.21%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 19.3M USD -6.57%
General and Administrative Expense 17.5M USD -11%
Operating Income (Loss) -42.3M USD -4.94%
Nonoperating Income (Expense) 1.41M USD +131%
Net Income (Loss) Attributable to Parent -39.7M USD -4.39%
Earnings Per Share, Basic -0.62 USD/shares +3.13%
Earnings Per Share, Diluted -0.62 USD/shares +3.13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.4M USD -70.9%
Assets, Current 15.6M USD -69.9%
Property, Plant and Equipment, Net 133K USD -53.8%
Operating Lease, Right-of-Use Asset 424K USD -64.1%
Assets 15.7M USD -70.5%
Accounts Payable, Current 582K USD +76.4%
Accrued Liabilities, Current 3.48M USD -34.5%
Liabilities, Current 4.32M USD -32.4%
Operating Lease, Liability, Noncurrent 66.8K USD
Liabilities 4.32M USD -35%
Retained Earnings (Accumulated Deficit) -487M USD -8.88%
Stockholders' Equity Attributable to Parent 11.4M USD -75.6%
Liabilities and Equity 15.7M USD -70.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.5M USD +9.46%
Net Cash Provided by (Used in) Financing Activities 28.7M USD
Net Cash Provided by (Used in) Investing Activities -7.44K USD -239%
Common Stock, Shares Authorized 150M shares +50%
Common Stock, Shares, Issued 64.5M shares +0.18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.5M USD -161%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.5M USD -42.2%
Deferred Tax Assets, Valuation Allowance 161M USD +7.59%
Deferred Tax Assets, Gross 162M USD +7.48%
Operating Lease, Liability 262K USD -74.1%
Depreciation 124K USD -35.3%
Payments to Acquire Property, Plant, and Equipment 7.44K USD +239%
Lessee, Operating Lease, Liability, to be Paid 268K USD -75.3%
Property, Plant and Equipment, Gross 2.64M USD +0.54%
Operating Lease, Liability, Current 262K USD -65%
Lessee, Operating Lease, Liability, to be Paid, Year Two 67.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 67.4K USD -91.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.51K USD -92.3%
Deferred Tax Assets, Operating Loss Carryforwards 88.7M USD +7.2%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 761K USD -32.3%
Additional Paid in Capital 498M USD +0.92%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 211K USD -39.8%
Share-based Payment Arrangement, Expense 4.45M USD +26.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%